RECALL-VAX™
Aβ vaccines represent a promising approach to develop disease-modifying agents for Alzheimer's disease, with potential not only to treat the disease but also to prevent its onset.

Aβ vaccines act by stimulating the immune system to produce antibodies that clear beta-amyloid peptides (Aβ) and prevent its further accumulation and deposition. Studies in animal models of Alzheimer's disease, as well as clinical studies, have shown that active immunization can result in clearance of amyloid plaques, prevent accumulation of Aβ, and arrest cognitive decline.

Intellect's active immunization technology, RECALL-VAX™, is focused on the development of chimeric peptide vaccines of very short, free-end fragments of Aβ linked to a well-characterized T-helper cell epitope, such as tetanus toxoid, against which most people have been vaccinated, which can elicit a memory response. These types of T-helper cell epitopes are particularly suitable for vaccines aimed at elderly populations because the memory response that they elicit facilitates activation of a senescent immune system.